Fast Plaque Clearance with Little ARIA? So Teases Trontinemab at AD/PD 2024
In a small dose-finding study, Roche’s new brain-shuttle-based anti-amyloid antibody mopped up nearly all plaques in three months, without triggering edema.
215 RESULTS
Sort By:
In a small dose-finding study, Roche’s new brain-shuttle-based anti-amyloid antibody mopped up nearly all plaques in three months, without triggering edema.
For a diagnostic test, specificity and sensitivity fall a little shy. Using two cut points might solve the problem.
The company announced it would halt its post-market trial and stop selling the drug; the rights to it now revert to Swiss company Neurimmune.
Based on exploratory endpoints and post hoc analyses, TauRx claims HMTM benefits a subgroup of participants with MCI. Trialists are unconvinced.
Backed up, the cells never transitioned into a disease-associated state, shirking their plaque compaction and synapse protection duties.